Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

Zachary A Cooper; Alexandre Reuben; Rodabe N Amaria; Jennifer A Wargo

doi:10.4161/21624011.2014.954956

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

Oncoimmunology. 2014 Dec 13;3(9):e954956. doi: 10.4161/21624011.2014.954956. eCollection 2014 Oct.

Authors

Zachary A Cooper¹, Alexandre Reuben², Rodabe N Amaria³, Jennifer A Wargo¹

Affiliations

¹ Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Genomic Medicine; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
² Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
³ Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.

Abstract

Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from patients on trial, however important questions remain regarding toxicity, optimal timing and sequence of therapy.

Keywords: BRAF; PD-1; PD-L1; immune checkpoint; melanoma.